• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconEli Lilly

Eli Lilly

Page 2 of 7
A young woman undergoes a brain scan.
HealthMeet the 24-year-old helping Lilly test a preventive Alzheimer’s drug
By Lindsey LeakeFebruary 6, 2025
Karsten Munk Knudsen, chief financial officer of Novo Nordisk A/S, at the company's headquarters in Bagsvaerd, Denmark, on Tuesday, Nov. 26, 2024.
HealthAs growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
By Ryan HoggFebruary 5, 2025
A person stands on a scale.
HealthHims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs
By Lindsey LeakeFebruary 3, 2025
The increase in online searches for obesity management drugs in recent years correlated to a surge in dispensed prescriptions, according to a new study from the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.
HealthOnline searches predicted the surge in prescriptions of weight-loss drugs like Wegovy and Zepbound, study says. Here’s what could happen next
By Lindsey LeakeJanuary 29, 2025
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
HealthHate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says
By Lindsey LeakeJanuary 21, 2025
Arianna Huffington
NewslettersExclusive: Arianna Huffington’s Thrive Global inks novel partnership with pharma giant Eli Lilly
By Alexa Mikhail and Nina AjemianJanuary 9, 2025
HealthElon Musk admits he takes an Ozempic-like weight-loss drug that RFK Jr. wants to restrict
By Alexa MikhailDecember 27, 2024
Novo Nordisk advertising flags and logo on facade, Danish pharmaceutical healthcare giant Novo Nordisk AS, production innovative drugs, obesity treatment Ozempic, Mainz, Germany June 15, 2024
HealthNovo Nordisk faces stock market bloodbath after weight-loss drug trial disappoints
By Ryan Hogg and AFPDecember 20, 2024
Close-up of a patient administering a dose of Zepbound (tirzepatide)
HealthZepbound vs. Wegovy: New clinical trial says this weight-loss medication sheds more pounds
By Lindsey LeakeDecember 4, 2024
RetailNovo Nordisk’s Wegovy sales jump on international rollouts
By Naomi Kresge and BloombergNovember 6, 2024
Alphabet CEO Sundar Pichai moves his hands as he talks during an interview
FinanceOver 25% of Google’s code is now written by AI—and CEO Sundar Pichai says it’s just the start
By Greg McKennaOctober 30, 2024
Despite the ubiquitousness of injectable GLP-1 drugs indicated for people with obesity, most Americans wouldn’t take them, according to a September 2024 survey from the Physicians Committee for Responsible Medicine.
HealthMost Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says
By Lindsey LeakeOctober 10, 2024
Tesla CEO Elon Musk attends the 10th Annual Breakthrough Prize Ceremony at Academy Museum of Motion Pictures.
HealthElon Musk and Bernie Sanders say they agree on one thing—cheaper Ozempic
By Christiaan HetznerSeptember 25, 2024
HealthRoche stock is falling after report its Wegovy challenger is causing patients to vomit
By Naomi Kresge and BloombergSeptember 12, 2024
NewslettersEli Lilly’s new CFO is a 23-year company veteran—showing how pharma firms rely on a ‘deep bench of qualified talent’
By Sheryl EstradaSeptember 10, 2024
1
  • 1
  • 2
  • 3
  • 4
  • 5
...7
Most Popular
Economy
Your grandparents are the reason the U.S. isn't in a recession right now. That won't last foreverAn image of a popular article
By Eleanor PringleMarch 1, 2026
AI
The week the AI scare turned real and America realized maybe it isn't ready for what's comingAn image of a popular article
By Nick LichtenbergFebruary 28, 2026
Success
Japanese companies are paying older workers to sit by a window and do nothing—while Western CEOs demand super-AI productivity just to keep your jobAn image of a popular article
By Orianna Rosa RoyleFebruary 27, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
Fortune Secondary Logo
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.